GCM
Graham Capital Management Portfolio holdings
AUM
$3.28B
1-Year Return
7.17%
This Quarter Return
+2%
1 Year Return
+7.17%
3 Year Return
+21.95%
5 Year Return
+42.01%
10 Year Return
+61.8%
AUM
$3.24B
AUM Growth
+$210M
(+6.9%)
Cap. Flow
-$1.09B
Cap. Flow
% of AUM
-33.53%
Top 10 Holdings %
Top 10 Hldgs %
29.67%
Holding
1,516
New
464
Increased
404
Reduced
281
Closed
321
Top Buys
| 1 |
Strategy Inc Common Stock Class A
MSTR
|
$34.1M |
| 2 |
PepsiCo
PEP
|
$18.1M |
| 3 |
Amazon
AMZN
|
$17M |
| 4 |
Johnson & Johnson
JNJ
|
$16.1M |
| 5 |
S&P Global
SPGI
|
$14M |
Top Sells
| 1 |
iShares Bitcoin Trust
IBIT
|
$78.5M |
| 2 |
VanEck Gold Miners ETF
GDX
|
$22.1M |
| 3 |
Microsoft
MSFT
|
$20.9M |
| 4 |
Walmart
WMT
|
$17.8M |
| 5 |
Citigroup
C
|
$16.9M |
Sector Composition
| 1 | Technology | 12.04% |
| 2 | Industrials | 8.43% |
| 3 | Financials | 7.1% |
| 4 | Consumer Discretionary | 6.67% |
| 5 | Healthcare | 4.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MREO
1126
Mereo BioPharma
MREO
$282M
| $77.7K | ﹤0.01% |
22,189
+9,490
| +75% | +$33.2K |
|
1127
BuzzFeed
BZFD
$68.9M
| $74.5K | ﹤0.01% |
+27,904
| New | +$74.5K |
|
1128
Mersana Therapeutics
MRSN
$34M
| $71.1K | ﹤0.01% |
1,989
+292
| +17% | +$10.4K |
|
|
NNDM
1129
Nano Dimension
NNDM
$293M
| $60.4K | ﹤0.01% |
24,356
+10,539
| +76% | +$26.1K |
|
1130
Larimar Therapeutics
LRMR
$337M
| $54.5K | ﹤0.01% |
+14,078
| New | +$54.5K |
|
|
OGI
1131
Organigram Holdings
OGI
$221M
| $53.2K | ﹤0.01% |
33,031
-12,403
| -27% | -$20K |
|
|
CRON
1132
Cronos Group
CRON
$957M
| $50K | ﹤0.01% |
24,774
-4,078
| -14% | -$8.24K |
|
1133
Safe Bulkers
SB
$455M
| $49.3K | ﹤0.01% |
+13,814
| New | +$49.3K |
|
1134
Pyxis Oncology
PYXS
$118M
| $47.2K | ﹤0.01% |
+30,287
| New | +$47.2K |
|
1135
Angi Inc
ANGI
$811M
| $46.5K | ﹤0.01% |
+2,799
| New | +$46.5K |
|
1136
Atea Pharmaceuticals
AVIR
$267M
| $41.9K | ﹤0.01% |
+12,511
| New | +$41.9K |
|
|
FSP
1137
Franklin Street Properties
FSP
$174M
| $40.7K | ﹤0.01% |
22,241
-5,576
| -20% | -$10.2K |
|
1138
Entravision Communication
EVC
$226M
| $40K | ﹤0.01% |
17,026
+6,175
| +57% | +$14.5K |
|
1139
Fate Therapeutics
FATE
$116M
| $36.9K | ﹤0.01% |
+22,342
| New | +$36.9K |
|
1140
Traeger
COOK
$200M
| $36.8K | ﹤0.01% |
+15,409
| New | +$36.8K |
|
1141
Clear Channel Outdoor Holdings
CCO
$656M
| $36.1K | ﹤0.01% |
+26,381
| New | +$36.1K |
|
|
VXRT
1142
DELISTED
Vaxart
VXRT
| $35.3K | ﹤0.01% |
53,331
+32,482
| +156% | +$21.5K |
|
1143
Aclaris Therapeutics
ACRS
$227M
| $35.1K | ﹤0.01% |
+14,172
| New | +$35.1K |
|
1144
Veru
VERU
$49.4M
| $34.3K | ﹤0.01% |
5,267
-6,928
| -57% | -$45.1K |
|
1145
Lyell Immunopharma
LYEL
$233M
| $33.4K | ﹤0.01% |
+2,607
| New | +$33.4K |
|
|
INZY
1146
DELISTED
Inozyme Pharma
INZY
| $33.4K | ﹤0.01% |
+12,044
| New | +$33.4K |
|
1147
Puma Biotechnology
PBYI
$253M
| $32.7K | ﹤0.01% |
+10,732
| New | +$32.7K |
|
1148
Gossamer Bio
GOSS
$668M
| $31.6K | ﹤0.01% |
+34,947
| New | +$31.6K |
|
1149
W&T Offshore
WTI
$261M
| $30.3K | ﹤0.01% |
18,268
-138,597
| -88% | -$230K |
|
|
ADAP
1150
Adaptimmune Therapeutics
ADAP
$10.9M
| $20K | ﹤0.01% |
37,195
+24,603
| +195% | +$13.3K |
|